Immuneering (IMRX) Equity Ratio (2020 - 2026)

Immuneering's Equity Ratio history runs 7 years deep, the most recent figure standing at 0.96 for Q1 2026.

• In Q1 2026, Equity Ratio rose 16.45% year-over-year to 0.96; the TTM figure through Mar 2026 stood at 0.96 (up 16.45% YoY), while the FY2025 annual figure was 0.94, up 19.96% from the prior year.
• Equity Ratio was 0.96 for Q1 2026 at Immuneering, up from 0.94 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.96 in Q1 2026 to a low of 0.72 in Q2 2025.
• Historically, Equity Ratio has averaged 0.89 across 5 years, with a median of 0.91 in 2023.
• The sharpest annual moves came in 2022 and 2025: Equity Ratio jumped 241.78% in 2022, then dropped 16.02% in 2025.
• A 5-year view of Equity Ratio shows it stood at 0.9 in 2022, then retreated by 1.65% to 0.88 in 2023, then slipped by 11.08% to 0.79 in 2024, then gained by 19.96% to 0.94 in 2025, then rose by 2.08% to 0.96 in 2026.
• The last three Equity Ratio figures came in at 0.96 (Q1 2026), 0.94 (Q4 2025), and 0.95 (Q3 2025), per Business Quant data.